Dimensional Fund Advisors LP Chemo Centryx, Inc. Transaction History

Dimensional Fund Advisors LP

$403 Billion
Q3 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 10, 2022	SELL	$22.17 - $51.8 $2.1 Million - $4.91 Million	-94,862 Reduced 48.53%	100,626 $5.2 Million
Q2 2022 Aug 12, 2022	SELL	$15.36 - $27.51 $1.92 Million - $3.43 Million	-124,852 Reduced 38.97%	195,488 $4.84 Million
Q1 2022 May 13, 2022	BUY	$22.22 - $39.12 $3.84 Million - $6.77 Million	172,958 Added 117.35%	320,340 $8.03 Million
Q4 2021 Feb 09, 2022	BUY	$18.38 - $40.5 $49,956 - $110,079	2,718 Added 1.88%	147,382 $5.37 Million
Q3 2021 Nov 12, 2021	BUY	$13.18 - $19.83 $127,476 - $191,795	9,672 Added 7.16%	144,664 $2.47 Million
Q2 2021 Aug 12, 2021	SELL	$9.59 - $50.88 $20,426 - $108,374	-2,130 Reduced 1.55%	134,992 $1.81 Million
Q1 2021 May 14, 2021	SELL	$49.53 - $68.4 $7.86 Million - $10.9 Million	-158,760 Reduced 53.66%	137,122 $7.03 Million
Q4 2020 Feb 25, 2021	BUY	$47.25 - $65.16 $14 Million - $19.3 Million	295,882 New	295,882 $18.3 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.